Tiapride for the Treatment of REM Sleep Behaviour Disorder in Dementia with Lewy Bodies: A Case Series

Table 1: Individual patient data.

Age [Years], Sex	Age at DLB Onset [Years]	Medication for DLB [mg/day]	Age at RBD Onset [Years]	RBD Duration [Years]	PSQI 5(h)		Motor and Vocal Behavior after 12 Weeks of Tiaprid		Final Tiaprid Dosage [mg]
Age [Years], Sex	Age at DLB Onset [Years]	Medication for DLB [mg/day]	Age at RBD Onset [Years]	RBD Duration [Years]	Before	After 12 Weeks	Patient	Bed Partner	Final Tiaprid Dosage [mg]
72, male	68	levodopa/carbidopa 200/50 rivastigmine patch 4.6	66	6	3	1	+	+	50*
73, male	70	levodopa/carbidopa 400/100 rivastigmine capsules 12 pramipexole 1,05	71	2	2	0	+	+	100
78, male	72	levodopa/carbidopa 600/150 rivastigmine patch 9.5 rotigotine patch 8	75	3	2	2	=	=	100
74, male	72	levodopa/carbidopa 400/100 rivastigmine patch 9.5	71	3	3	0	+	+	50
71, female	70	levodopa/carbidopa 300/75 donepezil 5	70	1	2	1	+	=	100
63, male	61	levodopa/carbidopa 300/75 donepezil 10	62	1	2	1	+	+	150

The individual patient data for DLB (dementia with Lewy bodies) and RBM (REM sleep behavior disorder) are given. Under “PSQI 5(h)” the patients’ answers to item 5(h) of the Pittsburgh Sleep Quality Index are listed. The perception of the nighttime motor and vocal behavior of the patient by the patient himself and his bedpartner are coded as “+” (improved), “=” (unchanged), “-“ (deteriorated).
*: This patient initially experienced a substantial improvement of sleep under a dosage of 50 mg tiaprid. Subsequent to increasing the dosage to 100 mg, sleep deteriorated. After having returned to the initial dosage of 50 mg, sleep improved again.